---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248487690.md"
description: "The Nasdaq Biotechnology Index rose by 1.11%. Among the constituent stocks, Prime Medicine increased by 10.46%, while Amylyx Pharmaceuticals, Lexicon Pharma, Kyverna Therapeutics, and Foghorn rose by 9.51% to 8.89%. In contrast, Amarin fell by 5.08%, Alpha Teknova dropped by 6.65%, and Q32 Bio saw a significant decline of 23.68%"
datetime: "2025-07-14T21:12:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248487690.md)
  - [en](https://longbridge.com/en/news/248487690.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248487690.md)
generator: "portal-rs"
---

# 

The Nasdaq Biotechnology Index closed up 1.11%. Component stock Prime Medicine rose 10.46%, while Amylyx Pharmaceuticals, Lexicon Pharma, Kyverna Therapeutics, and Foghorn rose between 9.51% and 8.89%. Amarin, on the other hand, fell 5.08%, Alpha Teknova dropped 6.65%, and Q32 Bio decreased by 23.68%

### Related Stocks

- [LXRX.US](https://longbridge.com/en/quote/LXRX.US.md)
- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)
- [TKNO.US](https://longbridge.com/en/quote/TKNO.US.md)
- [AMRN.US](https://longbridge.com/en/quote/AMRN.US.md)

## Related News & Research

- [Prime Medicine wins FDA IND clearance for PM647 in alpha-1 antitrypsin deficiency](https://longbridge.com/en/news/300070966.md)
- [Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency | PRME Stock News](https://longbridge.com/en/news/300071524.md)
- [Chardan Capital Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)](https://longbridge.com/en/news/300097621.md)
- [Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data](https://longbridge.com/en/news/299563280.md)
- [Amylyx Pharmaceuticals to present at Stifel virtual cardiometabolic forum fireside chat](https://longbridge.com/en/news/299899712.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**